Celldex (TCE2) AI Stock Analysis

Celldex

(Frankfurt:TCE2)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Phase 3 clinical progressStrong Phase 3 results materially improve barzolvolimab’s clinical and potential commercialization outlook. Efficacy was rapid, sustained, and observed in difficult-to-treat patients, while favorable safety through 24 weeks supports the candidate’s durability as Celldex advances toward commercialization.

Negative Factors

Near-zero commercial scaleNear-zero trailing revenue shows that Celldex has not yet established meaningful commercial scale and remains dependent on financing or other non-recurring sources. This limits internal funding capacity and leaves future financial performance highly dependent on clinical and partnering outcomes.

Celldex (TCE2) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 2.36B
Dividend Yield: ―
Average Volume (3M): 171
Price to Earnings (P/E): -6.9
Beta (1Y): 0.74
Revenue Growth: -97.44%
EPS Growth: -35.11%
Country: Germany
Employees: 198
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Celldex Business Overview & Revenue Model

Company Description

Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both infl...

Celldex Risk Analysis

Celldex disclosed 2 risk factors in its most recent earnings report. Celldex reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

1 New Risk

1.PART II — OTHER INFORMATION Item 1A. Risk Factors In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K may not be the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. There were no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K filed with the SEC on February 27, 2025.Q2, 2025

Celldex Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:TCE2 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NRIX	57Neutral	$2.93B	10.68	49.34%	―	738.76%	―
IOVA	55Neutral	$3.84B	-11.62	-40.51%	―	34.52%	41.20%
NUVB	54Neutral	$1.68B	-10.96	-49.73%	―	1083.56%	30.89%
NKTR	53Neutral	$1.33B	-5.80	-37.99%	―	-27.15%	23.10%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IMNM	37Underperform	$2.15B	-7.17	-50.56%	―	-100.00%	18.12%

* Healthcare Sector Average

Performance Comparison

DE:TCE2 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:TCE2	Celldex Therapeutics	26.40	5.20	24.53%
NKTR	Nektar Therapeutics	38.87	-17.15	-30.61%
IOVA	Iovance Biotherapeutics	8.48	6.66	365.93%
NRIX	Nurix Therapeutics, Inc.	26.80	14.54	118.60%
NUVB	Nuvation Bio Inc	4.76	-0.07	-1.45%
IMNM	Immunome, Inc.	18.21	2.80	18.17%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Celldex AI Stock Analysis